Shukra Pharmaceuticals Ltd
Shukra Pharmaceuticals Ltd (SHUKRAPHAR) last traded at ₹44.3, a market capitalisation of ₹1,946 crore, on a P/E of 57.3. Over the past 52 weeks the stock has ranged between ₹24 and ₹65.3. Shukra Pharmaceuticals Ltd last reported results for the quarter ended Jun 2026, with sales of ₹24 crore and net profit of ₹13 crore. Shukra Pharmaceuticals Ltd’s annual general meeting is scheduled for 25 Sept 2026. Figures are as of 25 Aug 2026 and are not real time.
Shukra Pharmaceuticals Ltd share price and key metrics
Metrics as of 25 Aug 2026. Not real time.
Shukra Pharmaceuticals Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹24 cr, up 380.0% from ₹5 cr a year earlier. Net profit was ₹13 cr, up 1200.0% year on year.
| ₹ crore | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|
| Sales | 11 | 13 | 5 | 6 | 39 | 6 | 24 |
| Expenses | 7 | 6 | 4 | 6 | 12 | 6 | 4 |
| Operating profit | 4 | 7 | 1 | -0 | 27 | 1 | 19 |
| OPM % | 37% | 55% | 24% | -7% | 69% | 11% | 81% |
| Other income | 1 | 1 | 1 | 2 | 1 | 1 | 1 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit before tax | 4 | 8 | 1 | 0 | 27 | 0 | 18 |
| Tax % | 23% | 29% | 26% | -1,090% | 24% | 553% | 29% |
| Net profit | 3 | 5 | 1 | 2 | 20 | -2 | 13 |
| EPS (₹) | 0.07 | 0.12 | 0.02 | 0.05 | 0.46 | -0.04 | 0.29 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Shukra Pharmaceuticals Ltd annual results
| ₹ crore | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|
| Sales | 33 | 57 | 75 |
| Operating profit | 13 | 29 | 47 |
| OPM % | 39% | 51% | 62% |
| Net profit | 10 | 22 | 34 |
| EPS (₹) | 0.22 | 0.50 | 0.76 |
TTM is the trailing twelve months to the most recent quarter.
Shukra Pharmaceuticals Ltd growth and returns
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- TTM
- 74%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- TTM
- 130%
- 10 Years
- 65%
- 5 Years
- 168%
- 3 Years
- 143%
- 1 Year
- 84%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- Last Year
- 29%
Shukra Pharmaceuticals Ltd shareholding pattern
Promoters held 51.16% at Aug 2026, broadly unchanged since Sep 2025. DIIs 0.11%.
| % held | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Aug 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 50.95% | 50.95% | 50.95% | 50.95% | 50.95% | 50.95% | 50.95% | 51.16% |
| DIIs | 0.11% | 0.11% | 0.11% | 0.11% | 0.11% | 0.11% | 0.11% | 0.11% |
| Public | 48.93% | 48.93% | 48.93% | 48.93% | 48.93% | 48.92% | 48.93% | 48.74% |
| No. of shareholders | 17,844 | 18,231 | 20,337 | 21,441 | 25,649 | 27,173 | 28,384 | 28,384 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
When is Shukra Pharmaceuticals Ltd’s AGM?
Shukra Pharmaceuticals Ltd’s annual general meeting is scheduled for 25 Sept 2026.
- AGM33rd Annual General Meeting and approval of name change to Shukra Medtech Limited
See the full results calendar for every Indian company reporting in the next 30 days.
Shukra Pharmaceuticals Ltd corporate filings
- AGM and Change of NameBoard Meetingmedium impact
Cruxal's analysis: Shukra Pharmaceuticals Limited has announced a strategic pivot, seeking shareholder…
Read the full analysis - Media ReleaseCompany Updatelow impact
Cruxal's analysis: Shukra Pharmaceuticals has issued a media release. The filing contains no specific…
Read the full analysis - Shukra Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 22/08/2026 ,inter alia, to consider and approve AGMBoard Meetingmedium impact
Cruxal's analysis: Shukra Pharmaceuticals Ltd. has announced a board meeting scheduled for August 22, 2026…
Read the full analysis - Reg 30 NSE LIsting DoneCompany Updatelow impact
Cruxal's analysis: Shukra Pharmaceuticals Ltd has formally completed the listing process on the National…
Read the full analysis - Reg 30 Change of name in objectCompany Updatelow impact
Cruxal's analysis: Shukra Pharmaceuticals has filed a Regulation 30 disclosure regarding a change in the…
Read the full analysis - Reg 30Company Updatelow impact
Cruxal's analysis: Shukra Pharmaceuticals Ltd has submitted a routine disclosure under Regulation 30 of the…
Read the full analysis - Media releaseCompany Updatelow impact
Cruxal's analysis: Shukra Pharmaceuticals has issued a media release dated August 14, 2026. The filing is a…
Read the full analysis - Newspaper PublicationCompany Updatelow impact
Cruxal's analysis: Shukra Pharmaceuticals Ltd has fulfilled a routine regulatory requirement under…
Read the full analysis - Quartely results June 30, 2026Board Meetinghigh impact
Cruxal's analysis: Shukra Pharmaceuticals Limited has announced its unaudited financial results for the…
Read the full analysis - The Board Meeting to be held on 11/08/2026 has been revised to 12/08/2026 Date of Board Meeting to be held on 11/08/2026 has been revised to 12/08/2026Board Meetinglow impact
Cruxal's analysis: Shukra Pharmaceuticals Ltd. has issued a formal intimation regarding the rescheduling of…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Track Shukra Pharmaceuticals Ltd
Cruxal reads every Shukra Pharmaceuticals Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.